share_log

Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary

Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary

2022年9月8日的重要生物技術催化劑-當天結束摘要
Benzinga Real-time News ·  2022/09/08 18:18
The United States Food and Drug Administration (FDA) has approved Revance Therapeutics' (NASDAQ:RVNC) lead asset DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the temporary improvement of moderate to severecfrown lines (glabellar lines) in adults. Revance shares traded as high as 22.39 percent, in a range of $22.02 to $25.47 on day volume of 8.73 million shares versus three months average volume of 729.3 thousand shares, closed regular trading session at $25.30.
美國食品和藥物管理局(FDA)已經批准瑞恩斯治療公司‘(納斯達克股票代碼:RVNC)注射用鉛資產DAXXIFY(達西肉毒毒素A-LAMM),用於暫時改善成年人中度至嚴重皺眉紋(眉間皺紋)。Revance的股價高達22.39%,在22.02美元至25.47美元的範圍內,當日成交量為873萬股,而三個月平均成交量為72.93萬股,收盤時常規交易時段為25.30美元。
Silence Therapeutics (NASDAQ:SLN) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its lead candidate SLN124 for the treatment of polycythemia vera (PV). Silence Therapeutics shares traded as...
沉默療法納斯達克(Sequoia Capital:SLN)宣佈,美國食...
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論